NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that its second-quarter revenues declined 3 percent year over year, as the diagnostics information services firm missed Wall Street estimates on the top and bottom line.

Quest had revenues of $1.82 billion for the three months ended June 30, compared to $1.88 billion for Q2 2012. It fell short of the consensus analysts' estimate of $1.84 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.